| |
| |
|
| Insider
Information: |
Glaxosmithkline Plc |
| Relationship: |
10% Owner |
| City: |
Brentford Middlesex |
| State: |
X0 |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
30 |
|
| Direct
Shares |
0 |
|
|
Indirect Shares
|
354,639,946 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$1,071,050,381 |
|
|
| Total
Shares |
354,639,946 |
|
|
| Total
Value |
$1,071,050,381 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
1
|
|
Stock
price went up :
|
2
|
1
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
2.0
|
1.0
|
| Percentage
Gain/Loss : |
 23.5%
|
18.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Quest Diagnostics Inc |
DGX |
Director, 10% Owner |
2004-06-25 |
0 |
2011-01-31 |
0 |
Premium* |
|
|
Redpoint Bio Corp |
RPBC |
10% Owner |
|
0 |
2007-03-12 |
7,456,899 |
Premium* |
|
|
Maxygen Inc |
MAXY |
10% Owner |
2003-08-05 |
0 |
2009-12-30 |
1,433,361 |
Premium* |
|
|
Amicus Therapeutics Inc |
FOLD |
Former 10% Owner (1) |
|
0 |
2014-10-27 |
0 |
Premium* |
|
|
Innoviva Inc |
INVA |
10% Owner |
2010-11-29 |
0 |
2021-05-20 |
0 |
Premium* |
|
|
Chemocentryx, Inc. |
CCXI |
Former 10% holder |
|
0 |
2018-10-16 |
0 |
Premium* |
|
|
Human Genome Sciences Inc |
HGSI |
Director, 10% Owner |
2012-07-30 |
0 |
2012-08-02 |
233,716,708 |
Premium* |
|
|
Response Genetics Inc |
RGDX |
10% Owner |
|
0 |
2012-09-13 |
5,000,000 |
Premium* |
|
|
Genocea Biosciences, Inc. |
GNCA |
10% Owner |
2014-02-10 |
0 |
2020-07-24 |
4,626,389 |
Premium* |
|
|
Concert Pharmaceuticals, Inc. |
CNCE |
Former 10% Owner |
2014-02-19 |
0 |
2014-02-19 |
1,356,533 |
Premium* |
|
|
Applied Genetic Technologies Corp |
AGTC |
Former 10% Owner |
2014-04-01 |
0 |
2015-02-23 |
1,436,448 |
Premium* |
|
|
Theravance Biopharma, Inc. |
TBPH |
Former 10% Owner |
|
0 |
2022-09-16 |
0 |
Premium* |
|
|
Htg Molecular Diagnostics, Inc |
HTGM |
Former 10% Owner |
2015-05-11 |
0 |
2017-03-27 |
792,781 |
Premium* |
|
|
Crispr Therapeutics Ag |
CRSP |
10% Owner |
2016-10-24 |
0 |
2016-10-24 |
3,220,627 |
Premium* |
|
|
Spero Therapeutics Inc |
SPRO |
10% Owner |
2017-11-06 |
0 |
2022-11-07 |
9,190,606 |
Premium* |
|
|
Translate Bio, Inc. |
TBIO |
10% Owner |
2018-07-02 |
0 |
2018-07-02 |
3,697,912 |
Premium* |
|
|
Liquidia Technologies Inc |
LQDA |
Former 10% holder |
2018-07-30 |
0 |
2018-07-30 |
624,422 |
Premium* |
|
|
Principia Biopharma Inc |
PRNB |
Former 10% Owner |
2018-09-18 |
0 |
2019-10-18 |
2,982,855 |
Premium* |
|
|
Turning Point Therapeutics, Inc. |
TPTX |
Director |
2019-04-22 |
0 |
2020-05-21 |
2,253,660 |
Premium* |
|
|
Bicycle Therapeutics Ltd |
BCYC |
10% Owner |
2019-05-28 |
0 |
2020-07-15 |
1,910,531 |
Premium* |
|
|
Morphic Holding, Inc. |
MORF |
Director |
2019-07-01 |
0 |
2019-07-01 |
2,633,772 |
Premium* |
|
|
Fulcrum Therapeutics, Inc. |
FULC |
|
2019-07-22 |
0 |
2019-07-22 |
1,785,714 |
Premium* |
|
|
Progyny, Inc. |
PGNY |
10% Owner |
|
0 |
2020-05-20 |
6,238,244 |
Premium* |
|
|
Orchard Therapeutics Plc |
ORTX |
Director, 10% Owner |
|
0 |
2020-01-01 |
12,455,252 |
Premium* |
|
|
Nkarta, Inc. |
NKTX |
Director, 10% Owner |
2020-07-14 |
0 |
2020-07-14 |
3,150,732 |
Premium* |
|
|
Pandion Therapeutics, Inc. |
PAND |
Director, 10% Owner |
2020-07-21 |
0 |
2020-07-21 |
2,248,304 |
Premium* |
|
|
Decibel Therapeutics, Inc. |
DBTX |
Director |
2021-02-17 |
0 |
2021-02-17 |
1,183,663 |
Premium* |
|
|
Lyell Immunopharma, Inc. |
LYEL |
10% Owner |
2021-06-21 |
0 |
2021-06-21 |
30,253,189 |
Premium* |
|
|
Cvrx, Inc. |
CVRX |
10% Owner |
2021-07-02 |
0 |
2021-07-02 |
1,007,583 |
Premium* |
|
|
Wave Life Sciences Ltd. |
WVE |
10% Owner |
|
0 |
2023-12-07 |
13,983,761 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
107 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MAXY |
Maxygen Inc |
10% Owner |
– – • |
2003-08-05 |
5 |
A |
$0.00 |
$0 |
I/I |
148,206 |
6,554,849 |
0 |
- |
|
| DGX |
Quest Diagnostics Inc |
10% Owner |
– – • |
2004-06-25 |
4 |
S |
$86.13 |
$101,333,495 |
I/I |
(1,176,518) |
20,952,154 |
|
- |
|
| DGX |
Quest Diagnostics Inc |
10% Owner |
– – • |
2004-12-14 |
4 |
S |
$94.19 |
$254,313,000 |
I/I |
(2,700,000) |
18,252,154 |
|
- |
|
| RPBC |
Redpoint Bio Corp |
10% Owner |
– – • |
2007-03-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,456,899 |
|
- |
|
| DGX |
Quest Diagnostics Inc |
Director |
– • • |
2009-03-17 |
4 |
S |
$45.50 |
$22,749,150 |
I/I |
(500,000) |
36,004,308 |
0 |
- |
|
| DGX |
Quest Diagnostics Inc |
Director |
– • • |
2009-03-18 |
4 |
S |
$45.67 |
$22,852,021 |
I/I |
(500,000) |
35,504,308 |
0 |
- |
|
| DGX |
Quest Diagnostics Inc |
Director |
– • • |
2009-03-19 |
4 |
S |
$44.33 |
$210,541,912 |
I/I |
(4,749,157) |
30,755,151 |
0 |
- |
|
| MAXY |
Maxygen Inc |
10% Owner |
– – • |
2009-12-30 |
4 |
S |
$5.30 |
$27,143,886 |
I/I |
(5,121,488) |
1,433,361 |
0 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
10% Owner |
– – • |
2010-11-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
6,866,244 |
|
- |
|
| INVA |
Innoviva Inc |
10% Owner |
– – • |
2010-11-29 |
4 |
B |
$22.50 |
$129,375,000 |
I/I |
5,750,000 |
5,750,000 |
1.5 |
- |
|
| DGX |
Quest Diagnostics Inc |
Director |
– • • |
2011-01-31 |
4 |
S |
$54.30 |
$1,690,226,243 |
I/I |
(30,755,151) |
0 |
0 |
- |
|
| INVA |
Innoviva Inc |
10% Owner |
– – • |
2011-02-18 |
4 |
B |
$23.70 |
$3,608,989 |
I/I |
152,278 |
5,902,278 |
1.5 |
- |
|
| INVA |
Innoviva Inc |
10% Owner |
– – • |
2011-05-03 |
4 |
B |
$25.60 |
$6,689,254 |
I/I |
261,299 |
6,163,577 |
1.5 |
- |
|
| INVA |
Innoviva Inc |
10% Owner |
– – • |
2011-07-21 |
4 |
A |
$0.00 |
$0 |
I/I |
9,401,499 |
15,565,076 |
0 |
- |
|
| INVA |
Innoviva Inc |
10% Owner |
– – • |
2011-08-02 |
4 |
B |
$19.71 |
$2,019,605 |
I/I |
102,466 |
15,667,542 |
1.5 |
- |
|
| INVA |
Innoviva Inc |
10% Owner |
– – • |
2011-11-01 |
4 |
B |
$22.23 |
$1,298,477 |
I/I |
58,411 |
15,725,953 |
1.5 |
- |
|
| CCXI |
Chemocentryx, Inc. |
10% Owner |
– – • |
2012-02-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
700,000 |
|
- |
|
| CCXI |
Chemocentryx, Inc. |
10% Owner |
– – • |
2012-02-13 |
4 |
A |
$0.00 |
$0 |
I/I |
6,643,492 |
7,343,492 |
0 |
- |
|
| INVA |
Innoviva Inc |
10% Owner |
– – • |
2012-02-14 |
4 |
B |
$18.12 |
$1,603,040 |
I/I |
88,468 |
15,814,421 |
1.5 |
- |
|
| INVA |
Innoviva Inc |
10% Owner |
– – • |
2012-05-16 |
4 |
B |
$21.29 |
$212,887,000 |
I/I |
10,000,000 |
25,814,421 |
1.5 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
10% Owner |
– – • |
2012-07-17 |
4 |
B |
$6.30 |
$18,582,360 |
I/I |
2,949,581 |
9,815,825 |
1.5 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
– • • |
2012-07-30 |
4 |
B |
$14.25 |
$70,320,088 |
I/I |
4,934,743 |
163,595,621 |
2.25 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
– • • |
2012-07-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
158,660,878 |
|
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
– • • |
2012-08-01 |
4 |
B |
$14.25 |
$81,035,689 |
I/I |
5,686,715 |
171,070,522 |
2.25 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
– • • |
2012-08-01 |
4 |
B |
$14.25 |
$25,481,651 |
I/I |
1,788,186 |
165,383,807 |
2.25 |
- |
|
107 Records found
|
|
Page 1 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
